Acino inaugurates new state-of-the-art patch factory in Germany

Acino inaugurates new state-of-the-art patch factory in Germany

08/03/2012 | 12:28pm US/Eastern
NEWS RELEASE

In the presence of senior government officials, customers and employees, Acino celebrated today the inauguration of its new pharmaceutical manufacturing plant for transdermal therapeutic systems at the company site in Miesbach (Germany).

The inauguration ceremony was attended by Arnfried Färber, Deputy District Adminis- trator of the County Miesbach, Ingrid Pongratz, First Mayor of the City Miesbach, repre- sentatives of Bayer Pharma AG, Luzi von Bidder, Chairman of the Board of Directors of Acino Holding Ltd., and Peter Burema, CEO of the Acino Group.

The new factory features state-of-the-art pharmaceutical manufacturing equipment and includes laboratories and modern storage space. Starting operations in the fourth quar- ter of 2012, it is scaled to increase the currently produced volume of 37 million patches per year by two to threefold. Furthermore, it allows for additional expansions in the fu- ture. In the mid-term, Acino expects to deliver an output of transdermal systems in a three-digit million range from the new facility alone. The new plant creates up to 40 new positions for highly skilled professionals and young apprentices. Total investment amounted to about EUR 20 million.

Acino's CEO Peter Burema commented: "Our operations here in Miesbach are thriving. We continue to invest in technological innovation and steadily grow the site in view of promising pipeline projects and thanks to the fruitful cooperation we enjoy with customers and authorities." Making reference to the new patch factory, he added: "We especially appreciate the close partnership with Bayer who paved the way for this new factory."

In June 2011, Acino and Bayer Pharma AG signed a multiyear manufacturing contract for the production of Bayer's novel contraceptive patch, currently in clinical Phase III, in support of its launch and global commercialization.
Already today, Acino Miesbach is the second largest manufacturer of transdermal patches in Europe.

Acino Holding Ltd.

Erlenstrasse 1

CH-4058 Basle

Phone +41 61 338 60 00

Fax +41 61 338 60 80 www.acino-pharma.com

Acino - Delivering Health
Acino (SIX: ACIN), a Swiss-based pharmaceutical company, develops, manufactures and internationally markets well-proven and innovative pharmaceuticals in novel drug delivery forms. Acino is a leader in advanced drug delivery technologies with a focus on modified release oral forms, oral dispersible forms, transdermal systems and extended release parenterals, for which it also holds patents. As a partner of pharmaceutical companies worldwide, Acino supplies finished in-house developed products and/or provides customized one-stop solutions from product development and registration to contract manufacturing, packaging and logistics. Under the brand "Acino Switzer- land", Acino markets Swiss-quality medicines in up and coming economies, currently in 80 coun- tries in the Middle East, Africa, Latin America and Asia. The Acino Group is headquartered in Basle, at present has about 850 employees (including staff members from Mepha) and generated annual revenues of EUR 135 million in 2011.

Contact Calendar
Robert Schmid

Media & Investor Relations Phone +41 61 338 61 15 [email protected]

www.acino-pharma.com

7.3.2013 Annual Report 2012

7.3.2013 Media and analyst conferences

4.4.2013 General Meeting of Shareholders

Acino Holding Ltd.

Erlenstrasse 1

CH-4058 Basle

Phone +41 61 338 60 00

Fax +41 61 338 60 80 www.acino-pharma.com

 

 

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.